Ascent Industries Co.

What they do

Ascent develops, manufactures and supplies surfactants, defoamers, lubricating agents, flame retardants and specialty intermediates in petroleum-based and bio-based formulations. It runs plants in Cleveland, Tennessee; Fountain Inn, South Carolina; and Danville, Virginia, serving energy, HII, personal care, CASE, agriculture, water treatment, pulp and paper, construction and automotive end markets. The company also provides custom manufacturing services including formulation development, process optimization, scale-up and commercial production, using both customer-dedicated and multi-purpose assets capable of blending, complex reaction chemistry and multi-step processing. It reports one segment, Specialty Chemicals, and trades on Nasdaq under ACNT.

Revenue drivers

• Specialty Chemicals (sole reportable segment) — All revenue comes from this segment's ingredients, process aids and custom manufacturing. Q2 2026 net sales were $25.7 million, up 37.6% year over year, on a 15.2% increase in pounds shipped and a 23.0% increase in average selling prices.
• Legacy organic business — The pre-acquisition base grew approximately 28% year over year in Q2 2026 and approximately 22% sequentially, per management commentary, and remains the bulk of revenue.
• Midwest Graphic Sales acquisition — Assets of Midwest Graphic Sales, Inc. and Sigma Coatings, Inc. were acquired on May 4, 2026. Midwest contributed $1.9 million of net sales and $0.3 million of Adjusted EBITDA in Q2 2026, with no net income.
• Custom manufacturing / CaaS services — Formulation development, blending, packaging, logistics and regulatory support are sold alongside products; sales cycles are described as solution-oriented and often measured in months or quarters.

Recent performance

Q2 2026 net sales were $25.7 million versus $18.7 million in Q2 2025, a 37.6% increase driven by volume and price. Gross profit rose 14.0% to $5.5 million, but gross margin fell to 21.6% from 26.1%, a 447 basis point decline. Net income was $0.7 million, or $0.07 diluted per share, versus a $2.4 million loss, or $0.25 per share, a year earlier. Adjusted EBITDA was $1.5 million (5.7% margin) versus negative $0.3 million. Six-month 2026 net sales were $45.1 million, up 23.6%, on an 11.5% volume increase and 14.6% higher average selling prices.

Strategy

Management introduced its Chemicals-as-a-Service (CaaS) strategy in 2025, organized around four pillars: Discovery & Development, Commercial & Contracting, Manufacturing and Fulfillment, and Service & Lifecycle Support. The goal is to compete on integrated service and problem-solving rather than product or capacity alone. A platform-wide optimization initiative is targeted to deliver $3 million to $5 million of annualized gross profit improvement by the end of 2026. The company is also pursuing disciplined acquisitions, with Midwest integrated ahead of schedule.

Risks

• Gross margin compression — Q2 2026 gross margin fell 447 basis points to 21.6% despite higher sales, and management said margin remains below prior-year level and long-term expectations.
• Weak end markets — Management described the specialty chemicals market as remaining soft, which could limit volume and pricing gains.
• Tariffs and trade policy — Recently implemented tariffs, potential additional tariffs and the February 20, 2026 Supreme Court IEEPA ruling and related Section 122 tariff create raw material cost and supply-chain uncertainty.
• Operating cash flow deterioration — The 10-K shows cash used in operating activities of $7.269 million in 2025 versus $0.977 million provided in 2024, driven by working capital changes including inventory and accounts payable.

Outlook

Management expects the platform-wide optimization initiative to reach a run-rate of approximately $3 million to $5 million in annualized gross profit improvement by the end of 2026. It cites continued commercial execution and the Midwest integration as evidence the strategy is delivering, with back-office integration complete a quarter early and manufacturing transition on schedule. The company says its strategy is unchanged and aims for consistent growth and higher returns on invested capital, while noting the specialty chemicals market remains soft and tariffs and inflation may pressure future sales and profitability.